On September 21, Bluebird Bio And Lonza Entered Into A Second Amendment To The Master Manufacturing Services Agreement, Dated June 3, 2016, As Amended October 23, 2017 – 8k
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293971/000129397123000046/blue-20230921.htm
Under the Lonza Agreement, Lonza manufactures drug product used for the Company’s gene therapies, ZYNTEGLO and SKYSONA.
